Of note, ACBP/DBI inhibition by Dbi knockout, Gabrg2 mutation, or KLH-ACBP/DBI vaccination resulted in reduced proliferation, both in tumor lesions (if detectable) and in the non-malignant hepatic parenchyma, irrespective of the precise oncogenic stimulus (CCl4 or DEN) (Figures S12A–S12E and S13). The gene discussed is GABRG2; the disease is neoplasm.